Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT06812052
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Retroperitoneal Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Radiation Therapy — RADIATION
    In this study, patients will receive a hypofractionated course of radiation therapy of 2.85 Gy x 15 fractions (42.75 Gy). If there are 2 or more patients with dose-limiting toxicities, the radiation course will be de-escalated to 2.7 Gy x 15 fractions (40.5 Gy).
  • Hypofractionationed Radiation Therapy — RADIATION
    This group is receiving hypofractionated radiation therapy (shorter course of RT)

Study Details

To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)

Key Dates

Start date
May 29, 2025
Status verified
May 2025
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
6 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Hypofractionated Radiation Therapy
    This group is receiving hypofractionated radiation therapy (shorter course of radiation therapy)

Primary Outcome Measure

Side effects from radiation therapy [ Time Frame: From enrollment to 30-days after the completion of radiation treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's Hospital / Dana Farber Cancer InstituteBostonMassachusetts02446
Miranda Lam
[email protected]
617-732-7948

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital / Dana Farber Cancer Institute· Boston, MA

Related Studies